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Recommendations
There is no evidence that conflicts with the previous 
recommendations published in the original version of the 
“Guidelines for the performance of fusion procedures for 
degenerative disease of the lumbar spine” regarding the 
use of hydroxyapatite (HA), various calcium-based prep-
arations, and recombinant human bone morphogenetic 
protein–2 (rhBMP-2) as bone graft extenders and substi-
tutes for lumbar fusion.48
No prior recommendations regarding the use of 
rhBMP-7 for lumbar fusions were published in the origi-
nal Lumbar Fusion Guidelines.
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In an attempt to enhance the potential to achieve a solid arthrodesis and avoid the morbidity of harvesting au-
tologous iliac crest bone (AICB) for a lumbar fusion, numerous alternatives have been investigated. The use of these 
fusion adjuncts has become routine despite a lack of convincing evidence demonstrating a benefit to justify added 
costs or potential harm. Potential alternatives to AICB include locally harvested autograft, calcium-phosphate salts, 
demineralized bone matrix (DBM), and the family of bone morphogenetic proteins (BMPs). In particular, no option 
has created greater controversy than the BMPs. A significant increase in the number of publications, particularly 
with respect to the BMPs, has taken place since the release of the original guidelines. Both DBM and the calcium-
phosphate salts have demonstrated efficacy as a graft extender or as a substitute for AICB when combined with local 
autograft. The use of recombinant human BMP-2 (rhBMP-2) as a substitute for AICB, when performing an interbody 
lumbar fusion, is considered an option since similar outcomes have been observed; however, the potential for het-
erotopic bone formation is a concern. The use of rhBMP-2, when combined with calcium phosphates, as a substitute 
for AICB, or as an extender, when used with local autograft or AICB, is also considered an option as similar fusion 
rates and clinical outcomes have been observed. Surgeons electing to use BMPs should be aware of a growing body 
of literature demonstrating unique complications associated with the use of BMPs.
(http://thejns.org/doi/abs/10.3171/2014.4.SPINE14325)
Key WorDs      •      lumbar spine      •      bone graft      •      bone substitute      •      fusion      •       
bone morphogenetic protein      •      practice guidelines
Abbreviations used in this paper: ACS = absorbable collagen 
sponge; AICB = autologous iliac crest bone; ALIF = anterior 
lumbar interbody fusion; b-TCP = b-tricalcium phosphate; BMA 
= bone marrow aspirate; CHA = coralline hydroxyapatite; CRM = 
compression-resistant matrix; DBM = demineralized bone matrix; 
FRA = femoral ring allograft; HA = hydroxyapatite; ICBG = iliac 
crest bone graft; IDE = investigational device exemption; mJOA = 
modified Japanese Orthopaedic Association; NRS = numeric rating 
scale; ODI = Oswestry Disability Index; OP-1 = osteogenic pro-
tein–1; PLIF = posterior lumbar interbody fusion; RCT = random-
ized controlled trial; rhBMP = recombinant human bone morphoge-
netic protein; SF-36 = 36-Item Short Form Health Survey; TLIF = 
transforaminal lumbar interbody fusion; VAS = visual analog scale. 
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Demineralized Bone Matrix
Grade C (Single Level III and Single Level V Studies)
The use of demineralized bond matrix (DBM) as a 
bone graft extender is an option for 1- and 2-level instru-
mented posterolateral fusions.
Hydroxyapatite/Calcium Extenders
Grade C (Single Level II Study)
The use of b-tricalcium phosphate (b-TCP)/local 
autograft as a substitute for autologous iliac crest bone 
(AICB) is an option for single-level instrumented postero-
lateral fusion due to comparable fusion rates and clinical 
outcomes.
Grade C (Single Level II Study)
The use of HA with local autograft/bone marrow as-
pirate (BMA) as a substitute for AICB in an option for 
instrumented posterolateral fusion due to comparable fu-
sion rates and clinical outcomes.
Grade C (Multiple Level V Studies)
The use of HA can be considered an option as a graft 
extender when mixed with AICB for instrumented pos-
terolateral fusions.
Grade C (Single Level IV and Multiple Level V Studies)
The use of calcium sulfate preparations mixed with 
local autograft, as a substitute for AICB, is an option for 
instrumented posterolateral fusions.
Grade I (Single Level V Study)
There is insufficient evidence to recommend for or 
against the use of a HA-glass/BMA composite as an au-
tograft substitute for posterolateral fusion.
rhBMP-2: Interbody Fusion
Grade B (Multiple Level II Studies)
The use of rhBMP-2 as a substitute for AICB for 
ALIF with threaded interbody cages is an option due to 
similar fusion rates and clinical outcomes.
Grade C (Single Level II Study)
The use of rhBMP-2 as a substitute for AICB for 
single-level PLIF is an option due to similar fusion rates 
and clinical outcomes; however, formation of heterotopic 
bone has been observed.
Grade C (Single Level IV and Multiple Level V Studies)
The use of rhBMP-2 as a bone graft extender can be 
considered as an option when performing a TLIF proce-
dure with a structural interbody graft.
Grade I (Single Level III Study)
There is insufficient evidence to make a recommen-
dation regarding the use of rhBMP-2 as a supplement for 
stand-alone ALIF procedures using femoral ring allograft 
(single Level III study) or with a resorbable spacer when 
performing TLIF procedures (single Level V study).
rhBMP-2: Posterolateral Fusion
Grade B (Multiple Level II Studies)
The use of rhBMP-2 supplemented with 15% 
HA/85% b-TCP matrix as a substitute for AICB is an 
option in single-level posterolateral instrumented fusions 
given the consistent observation of comparable fusion 
rate and clinical outcomes.
Grade C (Single Level II and Single Level IV Studies)
The use of rhBMP-2 supplemented with graft extend-
ers as an alternative to AICB is an option for single-level, 
instrumented posterolateral fusions in patients older than 
60 years.
Grade C (Single Level III and Single Level V Studies)
The use of rhBMP-2 as a graft extender with either 
AICB or local bone is an option in patients undergoing 
either instrumented or noninstrumented posterolateral fu-
sions.
Grade I
There is insufficient evidence to formulate a recom-
mendation regarding the use of rhBMP-2/local bone as a 
substitute for AICB when performing revision postero-
lateral fusions (single Level III study) or the use of rh-
BMP-2/calcium-based extenders for single level postero-
lateral fusions in patients who smoke and elect to undergo 
surgery for lumbar spondylosis (single Level III study).
rhBMP-2: Complications
Grade C (Multiple Level IV and V Studies)
The use of rhBMP-2 as a graft option has been as-
sociated with a unique constellation of complications that 
the surgeon should be aware of when considering the use 
of this graft extender/substitute.
rhBMP-7
Grade C (Single Level II Study)
The use of rhBMP-7 when combined with local auto-
graft as an alternative to AICB/local autograft is an option 
for single-level instrumented fusions based on equivalent 
clinical and radiographic outcomes. The use of rhBMP-7 
has not been approved by the FDA for spinal fusions and 
currently requires a humanitarian device exemption.
Grade I (Conflicting Level II Studies)
No recommendation regarding the use of rhBMP-7/
absorbable collagen sponge (ACS) as a substitute for 
AICB in posterolateral fusions can be made due to con-
flicting evidence from studies of equal strength.
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Rationale
The objective of a lumbar fusion is to create an en-
vironment that will allow bone to form a solid osseous 
bridge across the involved spinal segments. Autologous 
iliac crest bone has been considered the gold standard 
because of its ideal graft characteristics, including osteo-
conduction, osteoinduction, and osteogenesis.4,28,39 The 
harvesting of AICB, however, is commonly associated 
with increased postoperative pain, which may be under-
estimated by the treating surgeon.31,55 Additional draw-
backs of AICB include limited supply and increased op-
erative time and blood loss.
Allograft bone, one of the original substitutes for 
AICB, may avoid some of these drawbacks; however, 
when used alone, it is commonly associated with an in-
creased pseudarthrosis rate.28 For this reason, and to 
avoid the morbidity of harvesting AICB, a great deal of 
time and expense has been dedicated to investigate and 
promote extenders and/or substitutes of AICB. Potential 
candidates include locally harvested autograft, calcium-
phosphate salts, such as HA or b-TCP, and DBM. Howev-
er, no material has received more attention and generated 
more controversy than the family of BMPs. There are 
numerous papers that demonstrate the fusion potential 
of BMPs;2,7,18,19 however, complications associated with 
their use have been reported.29,47,50 Whether the benefits 
of BMPs justify the costs remains to be determined. Pos-
sibly more alarming than the potential complications and 
costs have been questions related to bias and conflict of 
interest associated with the reporting of results from tri-
als investigating the potential of BMPs.9 This escalating 
controversy prompted the editors of The Spine Journal 
to dedicate the June 2011 issue to concerns regarding the 
use of BMPs in spinal fusion surgery.
The objective of this update is to build upon the 
previous recommendations formulated in the original 
guidelines publication.48 A review of the recent medical 
literature was conducted to determine the utility of these 
materials with respect to their clinical efficacy, fusion 
potential, and complication risk. It is beyond the scope 
of the current update to comment on cost utility of these 
materials or the ethics of investigational reporting.
Search Criteria
A computerized search of the National Library 
of Medicine MEDLINE database, utilizing the on-
line search engine PubMed, was conducted from 2003 
through December 2011 utilizing the following search 
terms (((“Lumbosacral Region”[MeSH] OR “Lumbar 
Vertebrae”[MeSH]) AND “Spinal Fusion”[MeSH]) OR 
“lumbar fusion”[All Fields] OR (“lumbar”[title] AND 
“fusion”[title])) AND (((“Bone Substitutes”[MeSH] OR 
“Calcium Phosphates”[MeSH]) OR “Hydroxyapatites” 
[MeSH]) OR “Bone Morphogenetic Proteins”[MeSH]) 
AND ((“2003”[PDAT]: “3000”[PDAT]) AND “humans” 
[MeSH Terms] AND English[lang]). The search was 
limited to the English language and human subjects and 
yielded a total of 151 papers. The titles and abstracts of 
these articles were reviewed and those specifically inves-
tigating the fusion potential, clinical efficacy, and poten-
tial complications of bone graft substitutes and extenders 
were selected. Of these papers a secondary review of the 
bibliographies was conducted to identify any additional 
relevant papers. A total of 79 articles were selected and 
reviewed in detail. Studies supporting similar conclusions 
of equivalent strength were grouped together. Those pro-
viding the best evidence from these compilations were 
included in the evidentiary tables. A detailed description 
of high-level studies or a representative of lower-level 
studies of similar conclusions serve as the scientific foun-
dation for this update.
Scientific Foundation
Demineralized Bone Matrix
Since the publication by Urist, the osteoinductive 
properties of demineralized bone matrix (DBM) have 
been well recognized and extensively studied as both a 
substitute and extender of autograft bone.57 Cammisa et 
al. conducted a multicenter, prospective, controlled trial 
to investigate the potential of DBM as a graft extender 
for AICB when performing a posterolateral instrumented 
lumbar fusion (Table 1).8 One hundred twenty patients 
with a variety of degenerative disorders were enrolled 
and underwent up to a 3-level lumbar fusion. An inde-
pendent, blinded radiologist, utilizing static and dynamic 
radiographs, performed fusion assessment at 3, 6, 12, 18, 
and 24 months. The clinical outcome of these patients 
was not recorded. All patients served as his/her own con-
trol receiving AICB within one intertransverse space and 
an equal volume of DBM/AICB to the contralateral in-
tertransverse space. The follow-up rate at 24 months was 
68%. A comparable fusion rate was observed on both 
sides (52% with DBM/AICB and 54% with AICB). Sev-
enty-five percent of patients demonstrated fusion on both 
sides. Based on these observations the authors concluded 
that DBM could serve as an effective graft extender, de-
creasing the amount of autograft required and potentially 
reducing the risk and severity of donor site morbidity. 
Due to the utilization of internal controls, one cannot ex-
clude a possible interaction between the investigational 
and control groups that could affect the outcome. This 
is therefore considered a case series when determining 
baseline level of evidence. Additional limitations include 
a heterogeneous patient population with respect to pre-
senting diagnosis and the inclusion of a variety of fusions 
methods, including various interbody techniques. A large 
percentage of patients were lost to follow-up at 24 months. 
In the presence of pedicle screw stabilization, assessment 
of fusion with plain radiographs may be compromised. 
Secondary to these limitations, the case series was down-
graded to Level V evidence in support of DBM as a graft 
extender for AICB in posterolateral lumbar fusion.
Schizas et al. conducted a pilot study comparing the 
clinical and radiographic outcome of patients undergoing 
1- and 2-level posterolateral instrumented lumbar fusion 
using a novel DBM as a graft extender for autograft (Table 
1).51 Fifty-nine consecutive patients were divided into the 2 
treatment groups; 33 received DBM mixed with autograft/
BMA and 26 received only autograft. Fusion assessment 
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was performed 12 months after surgery by a blinded in-
dependent observer utilizing plain radiographs. Validated 
outcome measures, including the Oswestry Disability In-
dex (ODI) and visual analog scale (VAS) pain score, were 
used to determine clinical status. The fusion rate for the in-
terventional group was 69.7% and the control group 76.9% 
(p = 0.57). There was no difference in the clinical outcome 
between the 2 groups. The authors concluded that DBM is a 
safe and effective graft extender for single- and 2-level pos-
terolateral fusions. The relatively small number of patients, 
varying diagnoses, inadequate baseline demographic data, 
and short clinical follow-up all limit the conclusions of this 
study. The authors failed to standardized the volume and 
type of autograft used, whether AICB or locally harvested 
autograft. Due to these limitations the study is considered 
to provide only Level III evidence in support of DBM as a 
graft extender.
Calcium Phosphate Salts
This class of graft extenders and substitutes consists of 
calcium phosphate salts of varying composition that pro-
vide a lattice framework for in growth of new bone. These 
materials provide an osteoconductive matrix, having little 
if any osteoinductive or osteogenic properties. Examples 
include b-TCP, HA, and coral-based materials (Table 2).
β-Tricalcium Phosphate. Dai and Jiang performed a 
prospective, randomized, controlled trial to determine the 
efficacy of b-TCP as a bone graft substitute for AICB in 
single-level posterolateral instrumented fusions for degen-
erative spinal stenosis (Table 2).16 Sixty-two patients were 
randomized to one of 2 cohorts, receiving either b-TCP 
(n = 32) or AICB (n = 30), both supplemented with local 
autograft. An independent observer assessed clinical out-
come with validated outcomes measures, including mJOA, 
36-Item Short Form Health Survey (SF-36), and VAS for 
donor site pain, at 6 weeks and 3, 6, 12, 24 and 36 months 
after surgery. Two independent observers evaluated plain 
radiographs to assess fusion status at 3, 6, 12, 24, and 36 
months after surgery. No patients were lost to follow-up at 
36 months. The reported fusion rate for all study partici-
pants at 36 months was reported to be 100%, and signifi-
cant improvement in the clinical outcome was observed in 
all patients. No significant differences were observed be-
tween the treatment cohort and control group with respect 
to fusion rate or clinical outcome. A postoperative hemato-
ma was reported in 3 patients undergoing harvest of AICB. 
All patients from the AICB group reported donor site pain 
after surgery, and only 20% reported no pain at 6 weeks 
after the operation. In some patients (data not provided) 
pain was still present 36 months after surgery. The authors 
concluded that b-TCP, supplemented with local autograft, 
could serve as an effective substitute for AICB when local 
bone is insufficient. This was a well-designed and executed 
trial of a homogeneous group of patients with excellent 
clinical follow-up over an extended time. There were sev-
eral limitations, however, including a failure to describe the 
randomization process and failure to use a disease-specific 
outcome measure. The utilization of plain radiographs to 
determine fusion status may also be considered subopti-
mal, particularly in the presence of an instrumented fusion. 
Due to these limitations the study is downgraded to Level 
II evidence in support of utilizing b-TCP/local autograft as 
a substitute for AICB.
Hydroxyapatite. In 2005, Korovessis et al. conducted 
a prospective randomized controlled trial (RCT) to deter-
mine the fusion potential of coralline hydroxyapatite (CH) 
in multilevel, instrumented posterolateral lumbar fusions 
(Table 2).38 Sixty patients were randomized to one of 3 
cohorts: bilateral application of AICB, AICB on the left 
and CH/local bone/BMA on the right, and CH/local bone/
BMA bilaterally. Validated outcome measures, including 
the ODI, VAS, Roland-Morris score, and SF-36, were ob-
tained preoperatively and at 6, 12, 24, and 48 months after 
surgery. Two blinded, independent radiologists evaluated 
plain radiographs at 3, 6, 12, 24, and 48 months after sur-
gery, supplemented with CT imaging at 12 and 24 months, 
to assess fusion status. Ninety-five percent of patients were 
available for follow-up at a minimum of 3 years. The fu-
sion rate was 100% for all 3 groups at 1 year after sur-
gery, based on CT and plain radiographs; however, in the 
CH/local bone/BMA cohort the fusion was limited to the 
facet joint and lamina. Reliability of radiographic assess-
ment was adequate with an intraobserver and interobserver 
correlation coefficient (r) of 0.71 and 0.69, respectively. 
Improvement in all clinical outcome parameters was ob-
served; however, no statistical analysis was performed to 
determine if any intergroup differences existed. The au-
thors concluded that CH when combined with local bone/
BMA is an appropriate AICB substitute when placed over 
the lamina and facet; however, this is inappropriate for in-
tertransverse fusion. This was a comprehensive study of 
adequate design; however, the authors fail to provide ad-
equate baseline demographic data to determine if pretreat-
ment differences existed in the study groups. The authors 
avoided any limitations of utilizing an internal control by 
creating 2 additional study cohorts, those receiving only 
AICB and those receiving CH/local bone/BMA. Differ-
ences in clinical outcome are difficult to determine since 
no statistical analysis was performed. Due to these limita-
tions the study is considered to provide Level II evidence 
in support of the authors’ conclusions.
The objective of the single-center prospective cohort 
study conducted by Lee et al. was to determine the efficacy 
of a HA as a graft extender in instrumented posterolateral 
fusion (Table 2).41 Thirty-three patients with varying diag-
noses underwent either 1- or 2-level circumferential fusion 
with an HA/AICB mixture or AICB randomly applied to 
either the right or left intertransverse space. Equal volumes 
of graft material were used with the control arm receiving 
twice as much AICB as the investigational side, 6 versus 
3 ml, respectively. Radiographs, obtained at 3, 6, and 12 
months after surgery, and 3D thin-cut CT scans, obtained 
at 12 months, were independently reviewed to determine 
fusion status. Clinical outcome was not objectively re-
corded. The fusion status at 12 months was 86.7% in the 
investigational group and 88.9% in the control group. The 
volume of fusion was measured with CT and considered 
significantly greater on the investigational intertransverse 
space. The authors concluded that HA is a safe and ef-
fective graft extender for posterolateral lumbar fusion. A 
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major limitation of the study is the use of the contralat-
eral intertransverse space as the control arm in the study 
subjects. Interaction between treatment and control groups 
cannot be excluded; therefore, this is considered equivalent 
to a case series. Additional limitations include the small, 
heterogeneous population of patients and failure to include 
an objective assessment of clinical outcome. The study is 
considered to provide Level V evidence in support of HA 
acting as a graft extender for AICB.
Chang et al. performed a retrospective comparative 
study to determine if calcium sulfate mixed with local 
autograft could serve as an alternative to AICB for sin-
gle-segment posterolateral fusions (Table 2).12 One hun-
dred fifteen patients were divided between treatment and 
control groups and were observed for longer than 1 year. 
Fusion was assessed through static and dynamic radio-
graphs as well as reformatted CT images. Outcome was 
assessed utilizing VAS scores and ODIs. Similar fusion 
rates (92.3% for the treatment cohort [n = 66] and 92.9% 
for the control group [n = 49]) and clinical scores were 
observed between groups. This study benefitted from an 
accurate assessment of fusion and use of objective out-
come measures, but it is limited by the investigators’ 
failure to describe how patients were allocated to study 
cohorts, whether the evaluations were blinded, and an in-
adequate description of the statistical analysis. Because 
of these limitations, the study was downgraded to Level 
IV evidence in support of using a mixture of calcium sul-
fate and local autograft as a substitute for AICB.
Acharya et al. conducted a prospective cohort study to 
determine the efficacy of an HA-bioactive glass ceramic 
composite as a substitute for autologous bone (Table 2).1 
Twenty-four consecutive patients undergoing posterolater-
al instrumented lumbar fusion were entered into the study. 
Each patient served as his or her own control, with the 
left intertransverse space receiving a standard mixture of 
BMA and HA-glass ceramic composite and the right side 
receiving an equal volume of locally harvested autograft. 
Anteroposterior radiographs obtained 12 months after sur-
gery were evaluated by an independent orthopedic surgeon 
and were used to assess fusion status. The follow-up rate 
at 1 year after surgery was 91%. A definitive fusion was 
demonstrated on the control side in 73% of patients; how-
ever, there was no clear evidence of a fusion on HA/BMA 
side for any patient, with 77% of patients demonstrating 
complete resorption of the HA-bioactive glass/BMA graft. 
Given the dramatic difference in outcome, the principal in-
vestigator terminated the study and the authors concluded 
that this HA-glass composite/BMA was ineffective as a 
graft substitute in posterolateral lumbar fusion. Although 
this study suffers from a relatively small, heterogeneous 
patient cohort, the outcome assessment was performed in 
an objective manner with an adequate follow-up rate at 
the end point of the study. However, the use of an internal 
control is considered inadequate, as one cannot exclude an 
interaction between the control and treatment sides. Such 
an interaction would likely bias in favor of the treatment 
arm. Despite this inference, this study was considered 
equivalent to a case series and not a comparative cohort 
study. Although the observed results demonstrate a sig-




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M. G. Kaiser et al.
114  J Neurosurg: Spine / Volume 21 / July 2014
limitations necessitate an assignment of Level V evidence 
that HA-bioactive glass when combined with BMA cannot 
serve as a substitute for autologous bone.
A number of lower-quality studies and case series, 
providing Level IV and V evidence, have also been pub-
lished investigating the utility of various calcium-based 
graft extenders21,22,32 or substitutes for AICB.11,13,15,33,45 
These materials were generally mixed with either local 
autograft or BMA (Table 2). Given the nature of the study 
design, control groups were poorly designed, historical, 
or absent; therefore, direct comparisons to AICB are dif-
ficult and lack appropriate validity. When compared with 
previous published results, investigators considered the 
fusion rates acceptable; however, many of these studies 
are unable to provide data with respect to the actual clini-
cal benefit since baseline demographic data are not pro-
vided. Due to these limitations, these studies only dem-
onstrate the feasibility of utilizing these calcium-based 
materials as graft extenders or substitutes.
Bone Morphogenetic Proteins
Since the introduction of BMPs by Marshall Urist in 
1965,57 the application of these fusion agents, intended to 
induce bone formation from surrounding tissue, has dra-
matically increased. In 2002, the US FDA granted premar-
ket approval for the use of InFUSE (rhBMP-2, Medtronic 
Sofamor Danek) for single-level ALIF procedures from 
L-4 to S-1 when used in conjunction with the LT-CAGE 
Lumbar Tapered Fusion Device (Medtronic Sofamor 
Danek).58 Under a humanitarian device exemption, the 
FDA subsequently approved osteogenic protein–1 (OP-1; 
rhBMP-7, Stryker) for revision posterolateral lumbar spine 
fusion, where harvesting of autograft was not possible or 
not expected to achieve solid arthrodesis.60 Although the 
FDA had granted a similar approval for InFUSE/MAS-
TERGRAFT (rhBMP-2, Medtronic Sofamor Danek) for 
revision of symptomatic, posterolateral lumbar pseudar-
throsis, at the request of the sponsor, this device was with-
drawn in 2010.59 The use of these agents extends well be-
yond the FDA-approved applications, with approximately 
85% of primary spine procedures utilizing BMP consid-
ered off label.46 Although the off-label use of BMP for 
spine has met with radiographic and clinical success, con-
cern has been raised due to reports of rare but significant 
neurological or structural complications following the use 
of BMPs, particularly with interbody fusions.42,50 In addi-
tion, whether the routine use of BMPs is cost-effective has 
yet to be demonstrated. This uncertainty requires a careful 
evaluation of the literature investigating the various appli-
cations of the available BMPs.
rhBMP-2: Interbody Fusion. The utilization of rh-
BMP-2 as a substitute for AICB with threaded interbody 
cages for single-level ALIF procedures has been investi-
gated in 2 randomized control trials.5,6
The larger of the 2 trials was previously evaluated in 
the original Lumbar Fusion Guidelines and was desig-
nated as a Level I study.48 These higher-level studies were 
reevaluated for the purposes of this update since different 
criteria were used to determine levels of evidence and dif-
ferent recommendation grades formulated from the evi-
dence. After reviewing the paper by Burkus et al.,6 several 
limitations were identified including a failure to perform 
a power calculation to determine sample size, incomplete 
description of presenting demographic data (specifically 
no mention of comorbid medical conditions), and failure 
to perform an appropriate statistical analysis regarding 
outcomes between study cohorts (Table 3).
Burkus et al. also performed a prospective RCT in 42 
patients to determine fusion progression of rhBMP-2 in a 
threaded titanium cage compared with AICB for single-
level ALIF procedures.5 The investigational cohort (n = 
22) received rhBMP-2 and the control arm received AICB 
(n = 20). Fusion status was determined by 2 independent 
blinded radiologists evaluating both radiographs and CT 
images at 2 days and 6, 12, and 24 months after surgery. 
The fusion rate was 100% in the investigational cohort and 
95% in the control group. The patients receiving rhBMP-2 
demonstrated a greater average increase in bone density as 
demonstrated by Hounsfield units. The authors concluded 
that use of rhBMP-2 is associated with a high fusion rate 
and is a promising method to facilitate fusion in ALIF pro-
cedures. Given the dates of recruitment, these patients may 
have been included in a previous publication presented by 
the same authors and reviewed in the original Lumbar Fu-
sion Guidelines.6 This study focuses solely on the radio-
graphic outcome of these patients without any inclusion 
of clinical data. The number of patients in each cohort is 
relatively small and varies with respect to presenting diag-
nosis. Although this is an RCT, inadequate baseline demo-
graphic data are included and the authors failed to deter-
mine appropriate sample size prior to initiating the study. 
This study therefore provides Level II evidence in support 
of rhBMP-2 as a substitute for AICB for single-level ALIF 
procedures with threaded interbody cages (Table 3).
Haid et al. conducted a multicenter prospective ran-
domized controled study to investigate the clinical and 
radiographic outcomes of patients undergoing single-
level PLIF utilizing either iliac crest bone graft (ICBG) 
or rhBMP-2/ACS.29 Sixty-seven patients with single-level 
degenerative disc disease were randomized. Clinical out-
come was assessed utilizing validated outcome measures 
at 6 weeks and at 3, 6, 12, and 24 months after surgery. 
Radiographs and CT scans were obtained at 6, 12, and 
24 months after surgery. The follow-up rate at all time 
points was at least 89.6%. At 24 months after surgery the 
investigational group demonstrated a 92.3% fusion rate 
while only 77.8% were considered fused in the control 
group; this difference did not prove to be statistically sig-
nificant. Significant clinical improvement was observed 
in both cohorts, with the investigational group demon-
strated superior improvement in the back pain score at 24 
months. Although considered to be clinically irrelevant, 
a significantly greater percentage of patients in the in-
vestigational group (71% vs 12%), had heterotopic bone 
formation posterior to the interbody cage. Sixty percent 
of controls continued to complain of donor site pain at 24 
months. Due to concern regarding the significant increase 
in heterotopic bone formation, the authors terminated the 
study but concluded that these results were encouraging. 
Despite the lack of an observed consequence of this ex-
cessive bone formation, the authors elected not to con-
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tinue since the use of threaded titanium cages through 
the PLIF approach had fallen out of favor. The relatively 
small number of patients (< 50) in each cohort and the 
lack of a blinded clinical assessment limit conclusions 
formulated from this study. The study provides Level 
II evidence in support of using rhBMP-2 with threaded 
cages through the PLIF approach (Table 3).
Additional studies of lesser quality have explored the 
potential of rhBMP-2 as a graft extender for lumbar inter-
body fusion. Slosar et al. performed a prospective cohort 
study to determine the impact of rhBMP-2 on fusion rate 
and clinical outcome following ALIF with femoral ring 
allograft (FRA).54 Seventy-five patients with varying di-
agnoses and undergoing up to a 3-level fusion were en-
rolled; 30 control patients (n = 30) received an FRA with 
allograft croutons and an investigational group (n = 45) 
received an FRA supplemented with rhBMP-2/ACS. A sta-
tistically significant increase in fusion rate was observed 
at all time points for the investigational group compared 
with controls. Both groups demonstrated significant clini-
cal improvement at 12 and 24 months over baseline, but 
no significant difference was observed between treatment 
groups. A heterogeneous patient population with respect 
to presenting diagnosis and number of levels fused, an 
inadequate statistical analysis of potentially confounding 
baseline demographics, and failure to perform an indepen-
dent, blinded clinical assessment requires that the study be 
downgraded to Level III in support of rhBMP-2 as an ad-
junct to FRA interbody fusion (Table 3).
Several retrospective cohort studies and case series 
have investigated the use of rhBMP-2 as a graft extender 
when performing TLIF with an interbody graft. Rihn et al. 
performed a retrospective review of 48 patients receiving 
rhBMP-2 during TLIF procedures and observed a fusion 
rate of 95.8% at the 2-year follow-up with 71% reporting 
excellent or good outcomes.49 The complication rate was 
21.7% with one-quarter of these complications attributed 
to the use of rhBMP-2. Villavicencio et al. reviewed the 
data from 74 patients undergoing either open or minimally 
invasive TLIF for varying diagnoses using rhBMP-2 and 
allograft.67 The fusion rate for the entire cohort was 100%; 
however, a trend toward improved clinical outcome was 
observed for patients undergoing less invasive procedures. 
Mummaneni et al. conducted a retrospective cohort study 
intended to compare the efficacy of rhBMP-2 with AICB 
for TLIF.44 Forty-four patients underwent a TLIF, with 40 
patients (90%) available for a mean follow-up of 9 months. 
The control arm (n = 19) consisted of patients receiving 
AICB in an interbody spacer, while the investigational 
group (n = 21) received rhBMP-2 supplemented with either 
AICB (n = 12) or local autograft (n = 9). With at least 6 
months of follow-up, the fusion rate in the AICB group was 
95% and 100% in patients receiving rhBMP-2; however, 
only 76% of patients receiving rhBMP-2 were available for 
follow-up. At 6 months after surgery, 58% of patients con-
tinued to complain of donor site pain. The authors conclud-
ed that rhBMP-2 and local autograft is an excellent graft 
option and avoids donor site morbidity when performing a 
TLIF procedure. The relatively small, heterogeneous popu-
lation of patients with respect to diagnosis and surgery per-
formed limits these studies. Nonvalidated clinical outcome 
measures were used, and the method of fusion assessment 
is questionable given the presence of pedicle screw instru-
mentation. In the Mummaneni et al. study, neither the ra-
diographic evaluation nor assessment of clinical outcome 
was performed in an independent, blinded fashion. Due to 
the baseline study designs and various limitations, these 
studies provide at best Level IV or V evidence in support 
of rhBMP-2 as a supplement for interbody fusion through 
the TLIF approach (Table 3). Additional case series have 
been published exploring the potential of rhBMP-2 as a 
graft extender or substitute.7,24,40 Burkus et al. published a 
long-term clinical and radiographic companion study to 
their previous published report of patient undergoing single 
level ALIF procedures with stand-alone tapered cages and 
rhBMP-2/ACS.7 No significant difference in outcome at 6 
years was observed when compared with the previously 
published data obtained at 2 years after surgery. Geibel et 
al. reported a 100% fusion rate with an 89% patient satis-
faction rate in 48 patients undergoing 1- and 2-level instru-
mented PLIF with rhBMP-2 and posterolateral fusion.24 
Lanman and Hopkins published the only case series inves-
tigating the use of rhBMP-2 in conjunction with a biore-
sorbable cage.40 This study was limited by 64% of patients 
lost to follow-up at 12 months after surgery, compromis-
ing any attempt at a meaningful interpretation of the data. 
Since these studies are all case series with limitations, at 
best they provide only Level V evidence.
rhBMP-2: Posterolateral Fusion. In 2006, Dimar et 
al. reported the 24-month radiographic and clinical re-
sults of patients enrolled in an FDA investigational device 
exemption (IDE) study comparing rhBMP-2 combined 
with a compression-resistant  matrix (CRM; bovine type 
I collagen carrier containing 15% HA and 85% b-TCP) 
with AICB in instrumented posterolateral fusions (Table 
4).19 Ninety-eight of 150 randomized patients were avail-
able for review. Clinical outcome, assessed using vali-
dated outcomes instruments (SF-36, ODI, and back/leg 
pain scores), was performed at 6 weeks and 3, 6, 12, and 
24 months. Independent assessment of radiographs and 
CT images was performed at 6, 12, and 24 months. Op-
erative parameters, including the surgical time and blood 
loss, were significantly less in the rhBMP-2/CRM cohort. 
Both groups demonstrated a significant clinical improve-
ment compared with baseline, but not between treatment 
groups. The rhBMP-2/CRM cohort demonstrated a sta-
tistically higher fusion rate, 90.6% compared with 73.3%. 
At final follow-up, 16% of patients in the AICB cohort 
continued to complain of donor site pain. The authors 
concluded that rhBMP-2/CRM demonstrated similar 
clinical outcomes and improved fusion rates compared 
with AICB for single-level instrumented posterolateral 
fusions. Thirty-five percent of patients from the original 
cohort of randomized patients were lost to follow-up. This 
study included a heterogeneous patient population with 
respect to diagnosis. Due to these limitations the study 
was considered to provide level II evidence in support of 
rhBMP-2/CRM as a substitute for AICB.
Dimar et al. later reported the 2-year radiographic and 
clinical outcomes of a multicenter prospective random-
ized controlled IDE trial to investigate the use of rhBMP-2 
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matrix as a substitute for AICB for single-level postero-
lateral instrumented fusion (Table 4).20 Fusion assessment 
was performed in a blinded fashion, and clinical status was 
evaluated through validated outcome measures. Clinical 
follow-up was performed at 6 weeks and at 3, 6, 12, and 24 
months and radiographic follow-up at 6, 12, and 24 months. 
Four hundred sixty-three patients were randomized, with 
a 2-year follow-up rate of 89%. Significantly longer op-
erative times and greater blood loss was observed in the 
control group. There was no statistical difference in clini-
cal outcome between groups, although both demonstrated 
significant improvement compared with baseline scores. 
Donor site pain was reported in 60% of the control group 
at final follow-up. Based on CT imaging, the interventional 
group demonstrated a statistically superior fusion rate at 
6 months (79% with rhBMP-2 and 65% with AICB [p = 
0.002]) and at 24 months [96% with rhBMP-2 and 89% 
with AICB [p = 0.014]). The overall rate of adverse events 
was statistically similar; however, 17 graft-related compli-
cations were recorded in the control group. The authors 
concluded that the use of rhBMP-2 matrix improved op-
erative parameters, led to a higher fusion rate, and achieved 
comparable clinical outcomes to AICB and therefore can 
be considered an acceptable substitute for single-level pos-
terolateral instrumented fusion. This was a well-designed 
and well-executed study. It is not clear if the clinical as-
sessment was blinded; however, utilization of patient self-
assessment questionnaires decreases the likelihood of bias 
with reporting. The authors did not perform an appropriate 
power analysis to determine sample size and failed to pro-
vide information regarding patients lost to follow-up. Due 
to these limitations the study was downgraded to Level II 
evidence in support of rhBMP-2 matrix as a substitute for 
AICB.
Dawson et al. conducted a multicenter prospective 
RCT to investigate if rhBMP-2/ACS supplemented with 
an HA/TCP extender could serve as an appropriate sub-
stitute for AICB in instrumented posterolateral fusions 
(Table 4).17 Fifty patients were randomized; clinical fol-
low-up was performed at 3, 6, 12, and 24 months, and 
radiographic follow-up at 6, 12, and 24 months. At 24 
months, the follow-up rate was 88% in the treatment group 
and 86% in the control group. Both groups demonstrated 
improvements in all clinical outcome measures with the 
rhBMP-2 cohort demonstrating a trend toward better out-
comes. The fusion rate was higher at all time points in 
the rhBMP-2 cohort, with final fusion rates of 95% in the 
investigational group and 70% in the control group. No 
difference in the radiographic or clinical outcome proved 
to be statistically significant. The authors concluded that 
the combination of rhBMP-2 and HA/TCP could be an 
effective alternative to AICB for single-level posterolat-
eral instrumented fusions. The relatively small numbers 
of patients (< 50 patients per treatment arm), failure to 
provide adequate baseline demographic data, and utiliza-
tion of a nonvalidated composite score to assess overall 
success are limitations of the study. The study was there-
fore considered to provide Level II evidence in support 
of rhBMP-2/ACS and HA/TCP as a graft substitute for 
instrumented posterolateral fusions.
Glassman et al. conducted a prospective RCT to com-
pare the clinical and radiographic outcomes of 106 pa-
tients older than 60 years of age undergoing instrumented 
posterolateral fusions with either rhBMP-2/ACS or AICB 
(Table 4).26 The method of grafting was not standardized, 
with various graft extenders added at the discretion of the 
surgeon. Clinical outcome was determined with validated 
outcome measures, including SF-36, ODI, and numeric rat-
ing scale (NRS) for back and leg pain. Computed tomog-
raphy scans were used to assess fusion. At 24 months after 
surgery the clinical and radiographic follow-up was 94% 
and 93%, respectively. At baseline, the patients in the rh-
BMP-2 cohort reported leg pain with greater frequency (p 
= 0.031); there were no other differences in baseline demo-
graphics. The complication rate was significantly greater in 
the AICB cohort (20 vs 8, p = 0.014), although none of the 
complications were directly attributed to either the harvest 
of AICB or the use of rhBMP-2/ACS. Both cohorts dem-
onstrated a statistically significant clinical improvement 
over baseline; however, there was no difference in clini-
cal outcome between treatment groups. An 86.3% fusion 
rate was observed in the rhBMP-2/ACS cohort, compared 
with 70.8% in the AICB group. The authors provided a CT 
“grade” for the observed fusion with the rhBMP-2 cohort 
demonstrating a significantly higher score (4.3 vs 3.8 [p = 
0.03]). Nonunion requiring revision was reported in 1 pa-
tient in the rhBMP-2 cohort and 5 in the AICB group. An 
estimation of total cost over 2 years was calculated, and the 
difference between the 2 groups was not significantly dif-
ferent ($42,574 for the AICB cohort and $40,131 for the rh-
BMP-2/ACS cohort). The authors concluded that the study 
provided Level I evidence supporting the use of rhBMP-2/
ACS as an AICB replacement for lumbar fusion in the 
older patient. This study suffers from several limitations, 
including a heterogeneous patient cohort with respect to 
presenting diagnosis, failure to account for patients lost to 
follow-up, lack of a standard surgical protocol, question-
able “grading” scheme to assess fusion, failure to deter-
mine sample size through a power analysis, and failure to 
perform an adequate statistical analysis. Due to these limi-
tations the study was downgraded to Level II evidence in 
support of rhBMP-2 for patients older than 60 years of age 
undergoing posterolateral lumbar fusions.
Singh et al. published a prospective cohort study 
to compare outcome of patients receiving a mixture of 
rhBMP-2/local bone/AICB (n = 41) to those receiv-
ing only local bone/AICB (n = 11).53 Fusion assessment 
was performed in an independent, blinded manner with 
reformatted CT images. The fusion rate with rhBMP-2 
was 97% while the control cohort demonstrated a fusion 
rate of 77%. Those receiving rhBMP-2 were thought to 
achieve fusion faster and demonstrate a more robust fu-
sion. However, this study failed to provided an adequate 
description of baseline demographics (for example, the 
number of levels fused in each group). This is a small and 
heterogeneous population of patients; it is not clear if the 
surgical procedure was standardized between cohorts, 
and no objective clinical outcomes were reported. The 
study was therefore downgraded to Level III evidence in 
support of utilizing rhBMP-2 as an extender. 
Hamilton et al. published a retrospective case se-
ries of patients undergoing noninstrumented posterolat-
M. G. Kaiser et al.
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eral fusions utilizing local autograft supplemented with 
rhBMP-2.30 An 80% fusion rate was observed; 85% of 
patients were felt to demonstrate clinical improvement. 
This study provides only Level V evidence in support of 
rhBMP-2 as an extender with local bone for noninstru-
mented fusions due to the heterogeneous patient popula-
tion, failure to collect clinical outcomes in a prospective 
manner, and a radiographic follow-up rate of only 85%.
Taghavi et al. performed a retrospective cohort study 
to determine the efficacy of rhBMP-2/local bone to either 
allograft combined with bone marrow aspirate or autograft, 
in revision instrumented, posterolateral fusions. Sixty-two 
patients with varying diagnoses were included with a mini-
mum follow-up of 2 years.56 Patients were divided into 3 
groups: Group 1 (n = 24) received rhBMP-2, Group 2 (n = 
18) received BMA/allograft, and Group 3 (n = 20) received 
autograft. The exact source of autograft bone for Group 3 
was not clearly defined. All 3 cohorts received supplemen-
tal local bone. Static and dynamic radiographs were used 
to assess fusion and were reviewed by 3 blinded indepen-
dent reviewers with a diagnosis of nonunion based on either 
surgical exploration if revision performed or radiographic 
findings. Clinical outcome was determined through VAS 
scores. A fusion rate of 100% was observed for Groups 1 
and 3; however, Group 2 demonstrated a 77.8% fusion rate. 
Patients undergoing multilevel procedures with BMA/al-
lograft demonstrated a statistically lower fusion rate. No 
difference in VAS scores was observed. The authors con-
cluded that rhBMP-2 could be an appropriate alternative 
to AICB in revision posterolateral fusion. Although this 
study was well executed with appropriate follow-up, vali-
dated outcome measures, and appropriate assessment of 
fusion, due to the retrospective nature of the study design 
it provides Level III evidence. As this was the only study 
identified to investigate the use of rhBMP-2 in revision sur-
gery, evidence is insufficient to formulate a recommenda-
tion. Additional studies of similar or lesser quality, such as 
retrospective reviews or case series, promoting the use of 
rhBMP-2 for various clinical scenarios, such as in patients 
who use tobacco, have been published.3,25,27,36 Due to an in-
sufficient number of such studies no formal recommenda-
tions could be constructed regarding the use of rhBMP-2 
under the specific clinical circumstances.
rhBMP-2: Complications. Between 2003 and 2007, 
the annual number of procedures utilizing BMPs increased 
by 4.3-fold (from 23,900 to 103,194 cases), with spinal fu-
sions accounting for almost 93% of these cases.46 Although 
it is difficult to deny a positive impact on fusion rate, sur-
geons must be aware of the potential risks and complica-
tions related to the use of BMPs, particularly since the ma-
jority of procedures would be considered off label.
Rihn et al. performed a single-center retrospective co-
hort study to specifically identify complications associated 
with the use of rhBMP-2 for single-level TLIF procedures 
and to determine if these complications differed compared 
with the use of AICB.50 Between January of 2004 and May 
of 2007, 130 patients underwent a single-level TLIF using 
either AICB or rhBMP-2 (Table 5). One hundred nineteen 
patients were available for review, 33 receiving AICB and 
86 receiving rhBMP-2, with an average radiographic fol-
low-up of 19.1 months and an average clinical follow-up of 
27.6 months. A combination of plain radiographs and CT 
images were used to assess fusion status. Those patients 
receiving AICB demonstrated a 96.5% fusion rate, and the 
fusion rate in the rhBMP-2 cohort was 97% (p = 0.09). The 
overall complication rate was higher in the autograft cohort 
(45.5% vs 29.1%), but the difference was not significant. 
Donor site morbidity was the most common complication 
associated with AICB, and postoperative radiculitis was 
more often observed in the rhBMP-2 cohort (14% vs 3% [p 
= 0.08]). A significant decrease in radiculitis was observed 
after 2006 (20.4% to 5.4% [p = 0.047]), following the uti-
lization of a hydrogel sealant intended to shield the exiting 
root. Additional complications thought to be related to the 
use of rhBMP-2 included osteolysis and heterotopic bone 
formation. The authors concluded that the TLIF proce-
dure, regardless of graft, is associated with a relatively high 
complication rate (33.6% for the entire cohort). Although 
rhBMP-2 eliminates donor site morbidity, the surgeon 
should be aware of additional complications, such as radic-
ulitis, osteolysis, and heterotopic bone formation, that may 
be associated with its use. The authors failed to disclose if 
the assessment, clinical or radiographic, was performed in 
a blinded fashion. No validated outcome measures were 
used, and the fusion criteria were not adequately described. 
This study provides Level IV evidence supporting the use 
of rhBMP-2; however, more importantly, it highlights sev-
eral of the more common complications thought to be as-
sociated with the interbody application of rhBMP-2.
Pradhan et al. observed an increased rate of graft re-
sorption, fracture, or collapse in patients undergoing stand-
alone ALIF with femoral ring allograft.47 Lewandrowski 
et al. observed osteolysis of the vertebral endplate follow-
ing minimally invasive TLIF and speculated that endplate 
violation during interbody decortication may have been a 
contributing factor.42 Although not specific for lumbar pro-
cedures, Vaidya et al. observed a higher incidence of graft 
subsidence when rhBMP-2 was used with an allograft inter-
body spacer.66 Joseph and Rampersaud observed a greater 
incidence of heterotopic bone formation following the use 
of rhBMP-2 for minimal access interbody lumbar fusion, 
but no clinical sequelae associated with this excessive bone 
formation were identified.34 Mindea et al. observed a high-
er incidence of postoperative radiculitis of a nonstructural 
cause associated with the use of rhBMP-2 during minimal 
access TLIF procedures.43 Garrett et al. reported on the 
formation of painful postoperative seromas following the 
use of rhBMP-2 during posterolateral fusions.23 Finally, 
Carragee et al. identified a higher incidence of retrograde 
ejaculation in patients receiving rhBMP-2 during ALIF 
procedures.10 There have been a number of additional ret-
rospective reviews and case series that have corroborated 
the findings from these reports.3,14,37,52
Although a direct cause and effect relationship be-
tween the use of rhBMP-2 and these complications can-
not be formulated based on these studies, the potential 
association should not be ignored. The surgeon should 
carefully consider the off-label utilization of rhBMP-2, or 
any osteobiologic, and make sure that the patient has been 
adequately informed regarding these risks.
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rhBMP-7: Posterolateral Fusion. Osteogenic pro-
tein–1, also known as rhBMP-7, is another member of 
the transforming growth factor–b superfamily and plays 
a key role in osteoblast differentiation. Compared with 
rhBMP-2, there have been relatively few clinical stud-
ies investigating rhBMP-7 as an agent of spinal fusion, 
with the majority, if not all, focusing on posterolateral fu-
sion techniques. The FDA has not approved the use of 
rhBMP-7 for spinal fusions. Currently, its use requires a 
humanitarian device exemption. There were no recom-
mendations pertaining to the use of rhBMP-7 in the origi-
nal guidelines publication (Table 6).48
Delawi et al. published a prospective multicenter 
RCT comparing the efficacy of local autograft supple-
mented with either rhBMP-7 or AICB in single-level in-
strumented posterolateral fusions for isthmic or degen-
erative spondylolisthesis.18 Clinical and fusion assessment 
was performed at 6 weeks, and 3, 6, and 12 months after 
surgery. Fusion assessment through CT imaging was per-
formed in a blinded fashion. Validated clinical measures 
(ODI and VAS) were used to determine response to sur-
gery. The follow-up rate at 12 months was 89%. There 
was no statistical difference in the fusion rate between the 
groups (63% in the rhBMP-7 group and 67% in the AICB 
cohort). Both groups demonstrated clinical improvement 
compared with baseline scores, but  there was no statisti-
cal difference regarding clinical outcome between groups. 
At 12 months after surgery, 64% of AICB patients com-
plained of at least “mild” donor site pain (2.7 ± 2.8 VAS). 
No specific adverse event was related to AICB harvesting 
or use of rhBMP-7. The authors concluded that rhBMP-7 
is an effective alternative to AICB for supplementing lo-
cal autograft for single-level posterolateral fusions. The 
small sample size (< 50 patients), incomplete statistical 
analysis, and potential impact of differences in baseline 
characteristics requires that the study be downgraded to 
Level II evidence in support of utilizing rhBMP-7/local 
autograft as a substitute for AICB/local autograft in sin-
gle-level instrumented posterolateral fusions.
In 2008, Vaccaro et al. conducted a multicenter pro-
spective RCT to further investigate the safety and effi-
cacy of rhBMP-7/ACS and to demonstrate noninferiority 
as a replacement for AICB for noninstrumented, single-
level posterolateral fusion.62 Three hundred thirty-five 
patients were randomized in a 2:1 fashion, but only 293 
were treated (208 patients received rhBMP-7/ACS and 87 
received AICB). Independent blinded clinical and radio-
graphic evaluations were performed at 6 weeks and at 3, 
6, 12, 24, and longer than 36 months utilizing validated 
outcome measures, including ODI, SF-36, and VAS, and 
radiographs. Fusion assessment after 36 months was sup-
plemented with CT scans. The primary overall success 
was reported as a composite measure, intended for FDA 
submission, and required a 20% improvement in ODI, ab-
sence of treatment-emergent adverse events related to the 
device, absence of a decline in neurological status, and ra-
diographic successful fusion. At 24 months with a follow-
up rate of 87%, the investigational group did not achieve 
statistical equivalence with respect to the overall success 
rate compared with controls (38.7% compared with 49.4% 
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lower fusion rate (61.7% vs 83.1%). Noninferiority of the 
overall success was demonstrated after 36 months (47.2% 
in the investigational group and 46.8% in the control co-
hort [p = 0.025]). Computed tomography evaluation dem-
onstrated a statistically greater percentage of patients in 
the control arm demonstrating bridging bone across the 
intertransverse space (83% vs 56% [p = 0.001]). However, 
at 36 months after surgery, only 69% of the original 293 
patients were available for evaluation. There was no sig-
nificant difference in the rate of treatment-related serious 
adverse events between the investigational and control 
groups, 85.6% and 84.7% respectively (p = 0.863). No sig-
nificant immunological reaction related to the application 
of rhBMP-7 was recorded. The authors concluded that rh-
BMP-7/collagen composite is a safe and effective alterna-
tive to ICBG. This was a well-designed and executed trial; 
however, limitations exist. The randomization process was 
compromised as 13% of those originally randomized were 
not treated, and no data are provided regarding these pa-
tients or those lost at final follow-up. The method of fu-
sion assessment was altered at the final follow-up, with 
the addition of CT images, and a significant number of 
patients not available for evaluation (> 30%). Due to these 
limitations the study was downgraded to Level II evidence 
that rhBMP-7/ACS is noninferior to AICB for noninstru-
mented posterolateral lumbar fusion.
Kanayama et al. conducted a prospective RCT to com-
pare the clinical and radiographic outcomes in 20 patients 
with degenerative spondylolisthesis receiving either rh-
BMP-7/ACS (n = 10) or local autograft/HA/TCP (n = 10) 
for single-level posterolateral instrumented fusions.35 Fu-
sion status was assessed using plain radiographs and CT 
images at 3 and 6 weeks as well as at 3, 6, and 12 months 
after surgery. Validated clinical outcome measures (ODI) 
were obtained at 3, 6, 9, and 12 months after surgery. Re-
gardless of clinical status, all patients underwent a second 
surgery to remove their instrumentation if a solid arthrod-
esis was diagnosed based on radiographic imaging, on av-
erage 15.3 months following the index procedure. At 1 year 
after surgery the follow-up rate was 90%. The ODI scores 
significantly improved at 3 months in both cohorts; how-
ever, it is difficult to determine if the significance of this 
improvement was maintained beyond 3 months. The fu-
sion rate based on radiographic assessment was 78% in the 
rhBMP-7 cohort; however, only 57% of these patients dem-
onstrated a solid arthrodesis during direct surgical explora-
tion. The radiographic fusion rate of the control group was 
90%, with 78% of controls demonstrating a fusion at the 
time of implant removal. No statistical analysis regarding 
fusion rate was performed. The authors concluded that uti-
lization of rhBMP-7 was feasible, but the observed fusion 
rate was not encouraging, suggesting that modifications of 
the surgical technique or carrier were required. The study 
cohort was small yet homogeneous with respect to surgical 
procedure and presenting diagnosis. It is not clear if the ra-
diographic assessment was performed in a blinded fashion; 
however, confirmation of fusion through direct operative 
exploration is considered the gold standard for fusion as-
sessment. Limitations of the study design include failure 
to describe the randomization scheme or perform a power 
calculation to determine sample size. The authors failed 
to perform an adequate statistical analysis; this may be a 
secondary consequence of the small sample size. Despite 
the randomized nature of this study, the study was down-
graded to Level II evidence suggesting that rhBMP-7 is an 
inadequate substitute for AICB in instrumented posterolat-
eral fusion.
Vaccaro et al. published 3 separate studies over a 4-year 
period reporting the radiographic and clinical results from 
a prospective randomized controlled multicenter clinical 
pilot study investigating the efficacy and safety of OP-1 
compared with AICB in noninstrumented posterolateral 
lumbar fusions.61,64,65 The original pilot study, published in 
2004, randomized 36 patients with degenerative spondy-
lolisthesis to receive either rhBMP-7/ACS or AICB.64 The 
initial study followed patients at 6 weeks and at 3, 6, and 12 
months after the index procedure. An independent blinded 
radiologist evaluated plain radiographs to assess fusion 
and validated outcome measures; ODI and SF-36, were 
used to assess clinical status. At 12 months after surgery, 
the follow-up rate was 79% for the rhBMP-7 cohort and 
83% for the control group. No short-term adverse events 
directly related to the use of rhBMP-7 were reported. At 
12 months after surgery, the fusion and clinical success 
rates were 74% and 86%, respectively, for the rhBMP-7 co-
hort and 60% and 73%, respectively, in the control group, 
with no statistically significant difference between groups. 
From this initial study the authors concluded that rhBMP-7 
has an acceptable safety profile and comparable results to 
AICB to justify further investigation. This initial study was 
limited by the lack of a power calculation, a small sample 
size (< 50 patients), and significant loss to follow-up within 
the interventional group. A nonvalidated overall clinical 
outcome composite score is included that is difficult to ob-
jectify. Given these limitations, and those inherent with a 
pilot study, the initial publication is downgraded to Level 
II evidence in support of an acceptable safety profile and 
comparable efficacy of rhBMP-7 to AICB.
The same authors published 2 follow-up studies in 
2005 and 2008 to report the 2- and 4-year outcomes from 
the same study population.61,65 As the initial report provid-
ed Level II evidence, the subsequent reports were started at 
this level and downgraded further if additional limitations 
were identified. At the 24-month follow-up end point, the 
follow-up rate for the investigational and control groups 
were 86% and 83%, respectively.61 Radiographic fusion 
occurred in 55% of patients receiving OP-1 and 40% of 
AICB patients. Clinical success was recorded in 85% of 
OP-1 patients and 64% of control patients. No additional 
limitations were identified in this study; therefore, a Level 
II designation is maintained. However, at 48 months only 
69% and 61% were available for clinical and radiographic 
evaluations, respectively.65 The fusion and clinical success 
rates were reported as 68.8% and 73.7% in the rh-BMP-7 
group and 50% and 57.1% in the control cohort. Due to the 
small number of patients available at 48 months, formal 
statistical analysis was not performed. The authors con-
cluded that rhBMP-7 had an acceptable safety profile and 
comparable results to AICB. Due to the additional attrition 
of patients at the 48-month follow-up time point, this study 
was downgraded to Level III evidence in support of com-
parable efficacy between rhBMP-7 and AICB.
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In 2003, Vaccaro et al. conducted a pilot study to de-
termine the safety of rhBMP-7 combined with AICB for 
posterolateral uninstrumented fusions in patients with 
symptomatic degenerative spondylolisthesis.63 Seventy-five 
percent of patients achieved clinical success and 55% at-
tained a solid fusion. There were no adverse events spe-
cifically associated with the use of rhBMP-7. The authors 
concluded that rhBMP-7 demonstrated an acceptable safe-
ty profile when used as an adjunct to AICB. The small pa-
tient population, comparison with a historical cohort, and 
relatively short follow-up for a fusion procedure limit the 
study. Due to these limitations the study is downgraded to 
Level IV evidence. As this was the only study investigating 
this specific application of rhBMP-7, there is insufficient 
evidence to formulate a recommendation.
Summary
A wide variety of bone graft extenders and substitutes 
are currently available. Enhanced fusion rates and the 
ability to avoid complications associated with iliac crest 
harvesting are the intended benefits of their use. Many, if 
not all, of these extenders and substitutes evaluated in this 
review have demonstrated a positive effect on fusion rate 
with clinical outcomes comparable to AICB. Convincing 
evidence exists that calcium-based composites cannot be 
considered substitutes for AICB due to inferior fusion 
rates. These materials, along with allograft-derived grafts 
(DBM), function primarily as extenders, requiring some 
form of autograft to achieve adequate fusion rates. There 
has been little if any risk associated with the use of these 
extenders.
Bone morphogenetic proteins have dramatically al-
tered the landscape of spinal fusion surgery. These pow-
erful osteoinductive agents have demonstrated excellent 
potential as substitutes for AICB with both interbody and 
posterolateral fusions. The vast majority of investigations 
have evaluated the effect of rhBMP-2. Although rhBMP-2 
has shown a positive effect on fusion rate, complications 
have been reported related to its use. As a result, careful 
consideration is required when utilizing these products.
Despite the beneficial effect on fusion, the current 
literature has also not adequately addressed the issue of 
whether these improved fusion rates justify the cost, es-
pecially for treatment of routine degenerative lumbar dis-
ease. Although it is likely that certain patient populations 
would benefit from the addition of BMPs when perform-
ing spinal fusion surgery, the current literature has failed 
to adequately identify such patient populations.
Key Issues for Future Investigation
There has already been an extensive amount of re-
search investigating the potential impact of these graft 
extenders and substitutes. Further investigations should 
focus on improving study design to validate the conclu-
sions formulated from previous publications and a com-
prehensive evaluation of risks and complications will be 
necessary to properly inform our patients. Identification 
of patient populations at risk for pseudarthrosis would 
also better define patient populations where the benefits 
of utilizing BMPs justify the risks. Potentially more rel-
evant than defining the clinical impact of these materi-
als is to determine their cost utility. Comprehensive cost 
analyses, not simply a superficial quantification of upfront 
costs, will ultimately be required. Such an endeavor will 
require the concerted effort of a multidisciplinary panel 
of experts from the clinical, epidemiological, and admin-
istrative disciplines.
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